|
CelLBxHealth PLC shares fell on Monday as it reported a wider loss and lower revenue for 2025 in a ‘year of significant transition’. The Guildford, England-based liquid biopsy company, formerly called Angle PLC, said its pretax loss widened to £19.4 million in 2025 from £15.0 million a year earlier. Revenue fell 53% to £1.4 million from £2.9 million. Shares in CelLBxHealth were down 11% at 1.57 pence on Monday noon in London. The company said it has completed its operational restructuring, resulting in annualised cost savings of around £6.6 million. This includes a 60% reduction in headcount. ‘2025 was a year of significant transition for the company with decisive action taken to strengthen leadership, substantially reduce the cost base and reposition the business around a focused, partnership-driven strategy. We believe these changes have established a stronger operational and financial foundation for the future,’ said Executive Chair Jan Groen. ‘With a streamlined organisation, strengthened governance framework and growing strategic engagement from leading diagnostics and pharmaceutical partners, we are focused on disciplined execution and converting our commercial pipeline into sustainable revenue growth.’ Looking ahead, CelLBxHealth said further operational efficiencies were implemented during the first quarter of 2026, reducing headcount to 39 employees from 44. The firm said its pipeline has grown by 22% over the last quarter, with ‘significant interest’ across pharma and biotech. It expects 2026 revenue to rise to at least £2.1 million based on contracted revenue and near-term commercial opportunities. CelLBxHealth said it has a cash runway into the second quarter of 2027, due to its ‘much-reduced cost base and more efficient operating model’. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
